Voya Investment Management LLC Purchases 57,205 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Voya Investment Management LLC raised its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 342.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,914 shares of the company’s stock after acquiring an additional 57,205 shares during the quarter. Voya Investment Management LLC owned about 0.11% of EyePoint Pharmaceuticals worth $551,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of EYPT. Adage Capital Partners GP L.L.C. boosted its position in shares of EyePoint Pharmaceuticals by 51.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company’s stock valued at $42,838,000 after purchasing an additional 1,958,580 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 92.7% during the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock worth $27,620,000 after buying an additional 1,783,765 shares in the last quarter. Vanguard Group Inc. grew its position in shares of EyePoint Pharmaceuticals by 24.8% during the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock worth $28,334,000 after buying an additional 755,045 shares during the period. Blue Owl Capital Holdings LP bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at $4,974,000. Finally, Finepoint Capital LP lifted its position in shares of EyePoint Pharmaceuticals by 57.1% during the 4th quarter. Finepoint Capital LP now owns 1,111,104 shares of the company’s stock valued at $8,278,000 after acquiring an additional 403,700 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Stock Down 4.8 %

EYPT stock opened at $5.81 on Friday. The stock’s 50 day moving average is $6.02 and its 200-day moving average is $7.52. EyePoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $13.99. The firm has a market capitalization of $399.79 million, a PE ratio of -2.91 and a beta of 1.58.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. On average, equities research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on EYPT shares. Chardan Capital decreased their price target on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.29.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.